logo
Plus   Neg
Share
Email

AstraZeneca Reveals Safety Analyses Data For Movantik

AstraZeneca Plc (AZN) on Saturday revealed Movantik - naloxegol - had a similar incidence of adverse events among elderly patients as compared to placebo or usual care, in a presentation at the Digestive Disease Week 2015 in Washington, D.C.

The study evaluated the effects of daily oral administration of Movantik 12.5 mg or 25 mg versus placebo among outpatients 65 years and older with opioid-induced constipation and chronic non-cancer pain. The results came after further analysis of the Phase III KODIAC-04, KODIAC-05 and KODIAC-08 studies.

The incidence of adverse events reported among patients taking Movantik was similar to those taking placebo or usual care. Safety results among this subset were generally consistent with those seen in the overall patient populations from phase 3 studies.

The most common adverse reactions with Movantik as compared to placebo in clinical trials were: abdominal pain (21% vs. 7%), diarrhea (9% vs. 5%), nausea (8% vs 5%), flatulence (6% vs 3%), vomiting (5% vs 4%), headache (4% vs. 3%), and hyperhidrosis (3% vs. <1%)

Movantik is a once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain. When administered at recommended dose levels, Movantik decreases the constipating effect of opioids by blocking opioids from binding to mu-receptors in the bowel. And because of its design, at recommended doses, the CNS penetration of naloxegol is expected to be negligible, limiting potential interference with centrally mediated opioid analgesia.

AZN closed Friday at $69.29, down $0.81 or 1.16%, on a volume of about 1.27 million shares on the New York Stock Exchange.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney World, the Orlando, Florida-based entertainment complex, is easing the health safety guidelines that were rolled out to prevent the spread of the ongoing COVID-19 pandemic. The complex is ending temperature checks in a phased manner following the advice of the Centers for Disease Control and Prevention (CDC) and local health officials. Frito-Lay North America, the convenient foods division of food and beverages giant PepsiCo, Inc., is recalling select Ruffles All Dressed Potato Chips citing the possible presence of undeclared milk ingredients, a known allergen, the U.S. Food and Drug Administration said. According to the agency, the recalled products may have distributed regionally to Walmart's Sam's Club Warehouses. Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies initiated...
Follow RTT